Meeting
2024 ASCO Annual Meeting
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.
Authors
Guillermo De Velasco
Hospital Universitario 12 de Octubre, Madrid, Spain
Guillermo De Velasco , Piotr Rutkowski , Anna Maria Di Giacomo , Ana Maria Arance , Caroline Robert , Vanna Chiarion-Sileni , Ivan Marquez-Rodas , Jessica Kundapur , Julien Villaudy , Hans van Eenennaam , Laura Lassouw-Polman , Alexander M. Eggermont
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
2021-002623-38
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 9552)
DOI
10.1200/JCO.2024.42.16_suppl.9552
Abstract #
9552
Poster Bd #
336
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models.
First Author: Maria Jure-Kunkel
Poster
2018 ASCO Annual Meeting
Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).
First Author: Ari M. Vanderwalde
Poster
2015 ASCO Annual Meeting
A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain.
First Author: Kim Allyson Margolin
Poster
2022 ASCO Annual Meeting
A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).
First Author: Mehmet Akce